Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma

Bartholomew, J., Washington, T., Bergeron, S., Nielson, D., Saggio, J., Quirk, L.

Published online on July 25, 2016

Abstract

Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.